Q3 EPS Forecast for Neumora Therapeutics Raised by Analyst

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Investment analysts at HC Wainwright boosted their Q3 2026 earnings per share estimates for Neumora Therapeutics in a research report issued to clients and investors on Monday, August 17th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($0.20) for the quarter, up from their prior forecast of ($0.32). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Neumora Therapeutics’ Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.89) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.16) EPS, Q3 2027 earnings at ($0.19) EPS, Q4 2027 earnings at ($0.17) EPS, FY2027 earnings at ($0.68) EPS, FY2028 earnings at ($0.52) EPS, FY2029 earnings at $0.20 EPS and FY2030 earnings at $1.83 EPS.

Neumora Therapeutics (NASDAQ:NMRA) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.01.

A number of other equities analysts also recently issued reports on NMRA. Mizuho lowered their price target on Neumora Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a report on Thursday, June 18th. Royal Bank Of Canada lowered their target price on shares of Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Needham & Company LLC cut their price target on shares of Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, June 16th. Wall Street Zen upgraded shares of Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday. Finally, Weiss Ratings downgraded Neumora Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $6.57.

Neumora Therapeutics Trading Up 7.9%

NMRA opened at $1.64 on Wednesday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 5.09 and a current ratio of 5.09. Neumora Therapeutics has a one year low of $0.83 and a one year high of $3.65. The company has a market cap of $303.86 million, a P/E ratio of -1.33 and a beta of 2.75. The business’s 50-day simple moving average is $1.61 and its 200-day simple moving average is $2.11.

Institutional Trading of Neumora Therapeutics

A number of hedge funds have recently added to or reduced their stakes in NMRA. BlackRock Inc. purchased a new stake in shares of Neumora Therapeutics in the second quarter valued at about $13,246,000. Perceptive Advisors LLC purchased a new position in shares of Neumora Therapeutics during the 1st quarter worth approximately $9,953,000. ICONIQ Capital LLC acquired a new stake in shares of Neumora Therapeutics in the 2nd quarter valued at approximately $4,350,000. Siren L.L.C. boosted its stake in shares of Neumora Therapeutics by 35.1% in the first quarter. Siren L.L.C. now owns 8,497,822 shares of the company’s stock valued at $16,571,000 after buying an additional 2,209,039 shares in the last quarter. Finally, Johnson & Johnson acquired a new position in Neumora Therapeutics during the second quarter worth $3,144,057,000. 47.65% of the stock is owned by institutional investors and hedge funds.

More Neumora Therapeutics News

Here are the key news stories impacting Neumora Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $0.89 from a loss of $1.29 and increased its FY2027 forecast to a loss of $0.68 from $1.25. The revisions suggest the analyst expects Neumora’s losses to narrow faster than previously projected.
• Positive Sentiment: Longer-term estimates also improved materially: FY2028 EPS was raised to a loss of $0.52 from $1.10, FY2029 was upgraded to projected profit of $0.20 from a loss of $0.26, and FY2030 was increased to $1.83 from $1.51. These changes strengthen the potential profitability narrative for the biotechnology company.
• Positive Sentiment: Near-term quarterly forecasts were raised as well. HC Wainwright lifted its Q3 2026 EPS estimate to a loss of $0.20 from $0.32 and its Q4 2026 estimate to a loss of $0.16 from $0.30, indicating expectations for improved operating performance.
• Neutral Sentiment: HC Wainwright’s projections still show Neumora reporting losses through FY2028, while the company’s current-year consensus estimate remains a loss of $0.93 per share. Investors therefore remain dependent on clinical progress, funding, and execution before projected profitability is achieved.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.